<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Bras Ter Intensiva</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rev Bras Ter Intensiva</journal-id>
      <journal-id journal-id-type="publisher-id">rbti</journal-id>
      <journal-title-group>
        <journal-title>Revista Brasileira de Terapia Intensiva</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0103-507X</issn>
      <issn pub-type="epub">1982-4335</issn>
      <publisher>
        <publisher-name>Associa&#xE7;&#xE3;o de Medicina Intensiva Brasileira -
AMIB</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26761480</article-id>
      <article-id pub-id-type="pmc">4738828</article-id>
      <article-id pub-id-type="doi">10.5935/0103-507X.20150067</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Severe hypercalcemia as a form of acute lymphoblastic leukemia
presentation in children</article-title>
        <trans-title-group>
          <trans-title>Hipercalcemia grave como forma de apresenta&#xE7;&#xE3;o
de leucemia linfobl&#xE1;stica aguda em
crian&#xE7;as</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Andreia Lu&#xED;s</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moniz</surname>
            <given-names>Marta</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nunes</surname>
            <given-names>Pedro Sampaio</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abadesso</surname>
            <given-names>Clara</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Loureiro</surname>
            <given-names>Helena Cristina</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Duarte</surname>
            <given-names>Ximo</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Almeida</surname>
            <given-names>Helena Isabel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Pediatric Intensive Care Unit, Hospital Prof. Doutor
Fernando Fonseca, EPE - Amadora, Portugal.</aff>
      <aff id="aff2"><label>2</label>Department of Child and Adolescent Oncology, Instituto
Portugu&#xEA;s de Oncologia Lisboa, Francisco Gentil, EPE - Lisbon,
Portugal.</aff>
      <author-notes>
        <corresp id="c1"><bold>Corresponding author:</bold> Andreia Martins, Departamento de
Pediatria do Hospital Professor Doutor Fernando Fonseca, EPE; IC 19,
2720-276 - Amadora, Portugal. E-mail:
<email>andreialuismartins@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Oct-Dec</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Oct-Dec</season>
        <year>2015</year>
      </pub-date>
      <volume>27</volume>
      <issue>4</issue>
      <fpage>402</fpage>
      <lpage>405</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>9</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>11</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0">
          <license-p>This is an Open Access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Hypercalcemia is a rare metabolic disorder in children and is potentially
fatal. It has a wide differential diagnosis, including cancer. Here, we
report the case of a previously healthy 3-year-old who was admitted to the
emergency room with fatigue, hyporeactivity, fever and limping gait that
had evolved over 5 days and that was progressively worsening. On
examination the patient was unconscious (Glasgow coma score: 8). Laboratory
tests indicated severe hypercalcemia (total calcium 21.39mg/dL, ionized
calcium 2.93mmol/L) and microcytic anemia. Hyperhydration was initiated,
and the child was transferred to the pediatric intensive care unit.
Continuous venovenous hemodiafiltration with calcium-free solution was
instituted, which brought progressive normalization of serum calcium and an
improved state of consciousness. Zoledronate was administered, and
metabolic and infectious causes and poisoning were excluded. The bone
marrow smear revealed a diagnosis of acute lymphoblastic leukemia.
Hypercalcemia associated with malignancy in children is rare and occurs as
a form of cancer presentation or recurrence. Continuous venovenous
hemodiafiltration should be considered in situations where there is
imminent risk to life.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>A hipercalcemia &#xE9; um dist&#xFA;rbio metab&#xF3;lico raro em
pediatria, potencialmente fatal, apresentando um vasto diagn&#xF3;stico
diferencial, incluindo neoplasias. Relatamos aqui o caso de uma
crian&#xE7;a de 3 anos, previamente saud&#xE1;vel, admitida no
servi&#xE7;o de urg&#xEA;ncia por fadiga, hiporreatividade, febre e
claudica&#xE7;&#xE3;o da marcha com 5 dias de evolu&#xE7;&#xE3;o,
de agravamento progressivo. &#xC0; observa&#xE7;&#xE3;o,
apresentava-se inconsciente (escore de coma Glasgow: 8). Laboratorialmente,
apresentava hipercalcemia grave (c&#xE1;lcio total 21,39mg/dL, ionizado
2,93mmol/L) e anemia microc&#xED;tica. Iniciou
hiper-hidrata&#xE7;&#xE3;o e foi transferido para a unidade de cuidados
intensivos pedi&#xE1;tricos. Instituiu-se hemodiafiltra&#xE7;&#xE3;o
venovenosa cont&#xED;nua com soluto livre de c&#xE1;lcio, ocorrendo a
progressiva normaliza&#xE7;&#xE3;o da calcemia, com melhoria do estado
de consci&#xEA;ncia. Administrou-se zolendronato. Exclu&#xED;ram-se
causas metab&#xF3;licas, infecciosas e intoxica&#xE7;&#xE3;o. O
mielograma permitiu o diagn&#xF3;stico de leucemia linfobl&#xE1;stica
aguda. A hipercalcemia associada &#xE0; malignidade em pediatria &#xE9;
rara, ocorrendo como forma de apresenta&#xE7;&#xE3;o da neoplasia ou na
recorr&#xEA;ncia desta. Em situa&#xE7;&#xF5;es com risco de vida
iminente, deve se considerar hemodiafiltra&#xE7;&#xE3;o venovenosa
cont&#xED;nua.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Hypercalcemia</kwd>
        <kwd>Precursor T-cell lymphoblastic leukemia-lymphoma</kwd>
        <kwd>Hemodiafiltration</kwd>
        <kwd>Case reports</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Hypercalcemia is an uncommon metabolic disorder in children. The differential
diagnosis is complex and varies with age at presentation. Metabolic,
nutritional, drug-induced, genetic, inflammatory and neoplastic factors may also
be involved.<sup>(<xref rid="r1" ref-type="bibr">1</xref>)</sup></p>
      <p>Although common in adults, malignancy-associated hypercalcemia (MAH) is a rare
complication at pediatric age and occurs in 0.4 to 1.3% of cancers, of which
acute lymphoblastic leukemia is the most common in this age group.<sup>(<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>)</sup></p>
      <p>Treatment of MAH consists in the treatment of the underlying malignancy. In severe
and persistent hypercalcemia, the initial approach is hyperhydration.<sup>(<xref rid="r4" ref-type="bibr">4</xref>)</sup> As a part of standard
treatment, prednisolone is effective in cases of moderate severity.<sup>(<xref rid="r4" ref-type="bibr">4</xref>)</sup> Calcitonin is often reported
as a treatment for pediatric MAH but has a modest hypocalcemic effect and is not
marketed in Portugal. Bisphosphonates have been extensively studied and are
effective in adult MAH. However, due to the rarity of the disease in children
and the potential adverse effects with respect to osteogenesis, studies of
efficacy and safety in this age group are limited.<sup>(<xref rid="r4" ref-type="bibr">4</xref>)</sup> Nonetheless, small case series have confirmed
its effectiveness.<sup>(<xref rid="r5" ref-type="bibr">5</xref>)</sup> Severe
symptomatic hypercalcemia requires emergency correction with continuous
venovenous hemodiafiltration.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 3-year-old male child weighting 16kg with unremarkable past medical history
presented with tiredness that had evolved over 1 week. Five days before
admission, he started fever, left coxalgia and limping gait in the context of
recent trauma. Due to symptom maintenance, the child was re-evaluated 3 days
before admission. Imaging and laboratory studies did not suggest osteoarticular
infection, and the child was given symptomatic treatment. Since the clinical
picture persisted and was, accompanied by prostration, hyporeactivity and
refusal to eat, he returned to the emergency room.</p>
      <p>On admission, the patient was unconscious (Glasgow coma score: 8) with the
maintenance of osteotendinous reflexes. He was hemodynamically stable and did
not present any other alterations, such as rash, blood dyscrasia,
lymphadenopathy, hepatomegaly or splenomegaly.</p>
      <p>Laboratory evaluation revealed compensated metabolic alkalosis (pH of 7.41,
partial pressure of carbon dioxide [PaCO<sub>2</sub>] of 48.7mmHg, bicarbonate
[HCO<sub>3</sub>] of 32.5mmol/L and base excess of 9.6) and severe
hypercalcemia (total calcium 21.8mg/dL, ionized calcium 2.93mmol/L). Other
evaluations are shown in <xref ref-type="table" rid="t1">table 1</xref>.
Craniocephalic computed tomography and renal, abdominal and hip joint ultrasound
showed no significant changes.</p>
      <table-wrap id="t1" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <p>Evaluation performed on admission</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Analysis</th>
              <th rowspan="1" colspan="1">Result</th>
              <th rowspan="1" colspan="1">Reference value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Hemoglobin (g/dL)</td>
              <td align="center" rowspan="1" colspan="1">9.3</td>
              <td align="center" rowspan="1" colspan="1">11.5 - 11.5</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Hematocrit (%)</td>
              <td align="center" rowspan="1" colspan="1">26.6</td>
              <td align="center" rowspan="1" colspan="1">34 - 43</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Mean corpuscular volume (fL)</td>
              <td align="center" rowspan="1" colspan="1">73.1</td>
              <td align="center" rowspan="1" colspan="1">75 - 90</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Leukocytes (/uL)</td>
              <td align="center" rowspan="1" colspan="1">5,500</td>
              <td align="center" rowspan="1" colspan="1">4,000 - 12,000</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Neutrophils (/uL)</td>
              <td align="center" rowspan="1" colspan="1">2,300</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lymphocytes (/uL)</td>
              <td align="center" rowspan="1" colspan="1">2,500</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Platelets (/uL)</td>
              <td align="center" rowspan="1" colspan="1">186,000</td>
              <td align="center" rowspan="1" colspan="1">150,000 - 350,000</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">C-reactive protein (mg/dL)</td>
              <td align="center" rowspan="1" colspan="1">7.96</td>
              <td align="center" rowspan="1" colspan="1">&lt; 0,3</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Urea (mg/dL)</td>
              <td align="center" rowspan="1" colspan="1">60</td>
              <td align="center" rowspan="1" colspan="1">17 - 38.5</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Creatinine (mg/dL)</td>
              <td align="center" rowspan="1" colspan="1">0.83</td>
              <td align="center" rowspan="1" colspan="1">0.5 - 1.1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Albumin (g/dL)</td>
              <td align="center" rowspan="1" colspan="1">3.3</td>
              <td align="center" rowspan="1" colspan="1">3.6 - 5.2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Aspartate aminotransferase (UI/L)</td>
              <td align="center" rowspan="1" colspan="1">42</td>
              <td align="center" rowspan="1" colspan="1">10 - 47</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Alanine aminotransferase (UI/L)</td>
              <td align="center" rowspan="1" colspan="1">48</td>
              <td align="center" rowspan="1" colspan="1">24 - 49</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lactate dehydrogenase (UI/L)</td>
              <td align="center" rowspan="1" colspan="1">739</td>
              <td align="center" rowspan="1" colspan="1">155 - 280</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Alkaline phosphate (UI/L)</td>
              <td align="center" rowspan="1" colspan="1">121</td>
              <td align="center" rowspan="1" colspan="1">191 - 450</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Serum inorganic phosphorus (mg/dL)</td>
              <td align="center" rowspan="1" colspan="1">3.1</td>
              <td align="center" rowspan="1" colspan="1">4.0 - 6.0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Serum magnesium (mg/dL)</td>
              <td align="center" rowspan="1" colspan="1">1.1</td>
              <td align="center" rowspan="1" colspan="1">1.7 - 2.4</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Serum potassium (mmol/L)</td>
              <td align="center" rowspan="1" colspan="1">2.52</td>
              <td align="center" rowspan="1" colspan="1">3.5 - 5.0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Serum sodium (mmol/L)</td>
              <td align="center" rowspan="1" colspan="1">133</td>
              <td align="center" rowspan="1" colspan="1">135 - 145</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Given the clinical and laboratory severity of hypercalcemia, on suspicion of
osteoarticular infection, intravenous hyperhydration was initiated
(2,500mL/m<sup>2</sup>/day), and antibiotics were given (flucloxacillin and
gentamicin). The child was transferred to the pediatric intensive care unit.
Continuous venovenous hemodiafiltration was initiated after a 6.5F hemodialysis
central venous catheter was placed in the right femoral vein. An HF20 filter was
used and priming was performed with 5,000 UI of heparin in 1L of 0.9% sodium
chloride. Continuous venovenous hemodiafiltration was programmed in accordance
with the pediatric protocol (25 - 40mL/kg/h = 1/3 dialysis fluid + 2/3 fluid
replacement (2/3 prefilter + 1/3 post-filter)). Ultrafiltrate was calculated
according to the desired fluid balance.<sup>(<xref rid="r6" ref-type="bibr">6</xref>)</sup> A replacement and calcium-free dialysis solution was
used (Prism0Cal<sup>&#xAE;</sup>, Gambro - Lund, Sweden). Regional
anticoagulation was performed with machine-perfused unfractionated heparin, the
dose of which was adjusted according to the patient's activated partial
thromboplastin time. The technique was maintained for 72 hours and took place
without complications. As a therapeutic supplement, intravenous zoledronate
(0.025mg/kg) was administered on the third day of hospitalization. There was a
progressive decrease in total and ionized calcium levels and an improved state
of consciousness (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p>
      <p>
        <fig id="f1" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Evolution of total calcemia during hospitalization in the pediatric
intensive care unit.</p>
            <p>Grey area: total calcium reference value limits; black bars: period
under continuous venovenous hemodiafiltration; grey bars: period
under calcium supplementation. IPO - <italic>Instituto Portugu&#xEA;s
de Oncologia</italic>.</p>
          </caption>
          <graphic xlink:href="rbti-27-04-0402-g01"/>
        </fig>
      </p>
      <p>The investigation revealed low (unmeasurable) serum intact parathyroid hormone
(PTH) and excluded metabolic and infectious causes and vitamin or drug poisoning
(<xref ref-type="table" rid="t2">Table 2</xref>). Skeletal radiography
excluded osteolytic lesions.</p>
      <table-wrap id="t2" orientation="portrait" position="float">
        <label>Table 2</label>
        <caption>
          <p>Laboratory tests performed</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Analysis</th>
              <th align="center" rowspan="1" colspan="1">Result</th>
              <th align="center" rowspan="1" colspan="1">Reference value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">PTH intact</td>
              <td align="center" rowspan="1" colspan="1">&lt; 20</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PTHrp (pmol/L)</td>
              <td align="center" rowspan="1" colspan="1">1.2</td>
              <td align="center" rowspan="1" colspan="1">&lt; 2.0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">1.25 (OH)<sub>2</sub>D (pmol/L)</td>
              <td align="center" rowspan="1" colspan="1">2</td>
              <td align="center" rowspan="1" colspan="1">39 - 193</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">25 (OH)D (ng/dL)</td>
              <td align="center" rowspan="1" colspan="1">12.7</td>
              <td align="center" rowspan="1" colspan="1">30 - 100</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Retinol (ng/dL)</td>
              <td align="center" rowspan="1" colspan="1">21</td>
              <td align="center" rowspan="1" colspan="1">30 - 70</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ACE (U/L)</td>
              <td align="center" rowspan="1" colspan="1">20.10</td>
              <td align="center" rowspan="1" colspan="1">12 - 68</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">EBV-VCA IgM/IgG</td>
              <td align="center" rowspan="1" colspan="1">Negative/positive</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Parvovirus B19 IgM/IgG</td>
              <td align="center" rowspan="1" colspan="1">Negative/positive</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CMV IgM/IgG</td>
              <td align="center" rowspan="1" colspan="1">Negative/positive</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
<italic>Mycoplasma pneumoniae</italic> IgM/IgG</td>
              <td align="center" rowspan="1" colspan="1">Negative/negative</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">HIV 1/2</td>
              <td align="center" rowspan="1" colspan="1">Negative</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FT3 (pg/mL)</td>
              <td align="center" rowspan="1" colspan="1">2.31</td>
              <td align="center" rowspan="1" colspan="1">4.0 - 7.10</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FT4 (ng/dL)</td>
              <td align="center" rowspan="1" colspan="1">0.56</td>
              <td align="center" rowspan="1" colspan="1">0.9 -1.70</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">TSH (mUI/L)</td>
              <td align="center" rowspan="1" colspan="1">0.496</td>
              <td align="center" rowspan="1" colspan="1">0.8 - 7.5</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Total proteins (g/dL)</td>
              <td align="center" rowspan="1" colspan="1">5.6</td>
              <td align="center" rowspan="1" colspan="1">6 - 8</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Albumin (g/dL)</td>
              <td align="center" rowspan="1" colspan="1">2.53</td>
              <td align="center" rowspan="1" colspan="1">3.75 - 5.01</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Uric acid (mg/dL)</td>
              <td align="center" rowspan="1" colspan="1">9.4</td>
              <td align="center" rowspan="1" colspan="1">3.0 - 5.5</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN1">
            <p>PTH - parathyroid hormone; PTHrp - parathyroid hormone-related
protein; 1.25 (OH)<sub>2</sub>D - 1.25-dihydroxy-vitamin D;
25(OH)D - Vitamin D in the form of 25-hydroxyvitamin D; ACE -
angiotensin converting enzyme; EBV-VCA - viral capsid antigen of
the Epstein-Barr virus; CMV - cytomegalovirus; HIV - human
immunodeficiency virus; FT3 - free T3 hormone; FT4 - free T4
hormone; TSH - thyroid stimulating hormone.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>During hospitalization, progressive pancytopenia (hemoglobin 7.7g/dL, leukocytes
2200/uL, platelets 67000/uL) was identified and bone marrow examination was
performed, which confirmed precursor B-cell acute lymphoblastic leukemia.</p>
      <p>After diagnosis, the child was transferred to a pediatric oncology referral
center, where, after further review, remission induction therapy was started
(2005 ALL-DFCI protocol of the Dana-Farber Cancer Institute). The complementary
evaluation by flow cytometry revealed 69% infiltration of B lymphoblasts. During
hospitalization, there were periods of asymptomatic hypocalcemia (minimum
5.9mg/dL at day 10 post-zoledronate), which required intravenous correction. A
bone marrow smear performed 4 weeks after the beginning of induction therapy
confirmed complete remission both morphologically and by molecular biology.</p>
      <p>Currently, approximately 10 months after starting treatment, the child remains in
remission.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Hypercalcemia is a potentially fatal disorder, regarding its neurological and
cardiac complications. The treatment includes hyperhydration, bisphosphonates
and treatment of the underlying disease.<sup>(<xref rid="r1" ref-type="bibr">1</xref>)</sup> Occasionally, rapid correction of the disturbance
becomes crucial, particularly in the setting of loss of consciousness or when
the hypercalcemia is refractory to conventional measures. In such situations,
the use of continuous venovenous hemodiafiltration has been identified as an
effective treatment.<sup>(<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>)</sup> Its successful use in severe
hypercalcemia has been reported in adults,<sup>(<xref rid="r8" ref-type="bibr">8</xref>-<xref rid="r11" ref-type="bibr">11</xref>)</sup> but the use
of the technique in pediatrics has rarely been described in the
literature.<sup>(<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r12" ref-type="bibr">12</xref>)</sup> In this case report, due to
severe hypercalcemia on admission, the use of dialysis solution with
calcium-free replacement was chosen. Regular analytical calcemia controls were
performed in order to avoid a sudden decrease and below-normal values. The renal
replacement therapy settings were set in order to provide a gradual decrease in
serum calcium, thereby avoiding complications such as circuit clotting. As the
patient did not present spontaneous diuresis, it was decided to program losses
to ensure a neutral fluid balance. Following clinical and laboratory
stabilization, zoledronate was introduced to maintain normocalcemia, as the
effect of continuous venovenous hemodiafiltration is temporary.<sup>(<xref rid="r11" ref-type="bibr">11</xref>)</sup> Continuous monitoring of
serum calcium levels was assured due to the risk of hypocalcemia observed in
this case.<sup>(<xref rid="r13" ref-type="bibr">13</xref>)</sup></p>
      <p>The etiological investigation suggested an independent PTH mechanism. Metabolic
and infectious causes and vitamin or drug poisoning were excluded. Progressive
pancytopenia led to the suspicion of MAH, which ultimately led to the final
diagnosis.</p>
      <p>The pathogenesis of MAH includes the stimulation of bone resorption, mediated by
proteins and cytokines produced by the tumor cells or by the tumoral
microenvironment. Two distinct mechanisms are described, which include
hypercalcemia by local osteolytic lesions (bone metastasis) and humoral
hypercalcemia by the activation of RANK-RANKL (receptor activator of nuclear
factor &#x3BA;B and its ligand). Parathyroid hormone-related protein (PTHrP) is
the most frequently involved mediator, but other mediators, such as interleukin
(IL)-1, IL-6, tumor necrosis factor alpha (TNF-&#x3B1;), transforming growth
factor beta (TGF-&#x3B2;), prostaglandins and even calcitriol and ectopic PTH
production may be involved.<sup>(<xref rid="r4" ref-type="bibr">4</xref>)</sup></p>
      <p>In acute lymphoblastic leukemia, an association with hypercalcemia in patients
with t (17;19) has been reported, suggesting the possible induction of
PTHrP.<sup>(<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r14" ref-type="bibr">14</xref>)</sup> In this case, this
cytogenetic abnormality was not observed, and high levels of PTHrP were not
detected, thus excluding this mechanism as the <italic>primum movens</italic> of
hypercalcemia.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>CONCLUSION</title>
      <p>The described case shows an infrequent complication, not only at pediatric age,
but also in children with oncological diseases, suggesting that this metabolic
emergency unveils of the underlying disease. Continuous venovenous
hemodiafiltration with calcium-free solution as a first-line treatment in cases
of severe and symptomatic hypercalcemia was found to be effective in the rapid
induction of normocalcemia and neurological improvement, buying valuable time
until maintenance treatment focused on the etiology can exert a sustained
effect.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p><bold>Conflicts of interest:</bold> None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>Responsible editor:</bold> Jefferson Piva</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lietman</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Germain-Lee</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Hypercalcemia in children and adolescents</article-title>
          <source>Curr Opin Pediatr</source>
          <year>2010</year>
          <volume>22</volume>
          <issue>4</issue>
          <fpage>508</fpage>
          <lpage>515</lpage>
          <pub-id pub-id-type="pmid">20601885</pub-id>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKay</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Furman</surname>
              <given-names>WL</given-names>
            </name>
          </person-group>
          <article-title>Hypercalcemia complicating childhood
malignancies</article-title>
          <source>Cancer</source>
          <year>1993</year>
          <volume>72</volume>
          <issue>1</issue>
          <fpage>256</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="pmid">8508415</pub-id>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inukai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirose</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Inaba</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kurosawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hama</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Inada</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hypercalcemia in childhood acute lymphoblastic leucemia:
frequent implication of parathyroid hormone-related peptide and
E2A-HLF from translocation 17;19</article-title>
          <source>Leukemia</source>
          <year>2007</year>
          <volume>21</volume>
          <issue>2</issue>
          <fpage>288</fpage>
          <lpage>296</lpage>
          <pub-id pub-id-type="pmid">17183364</pub-id>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sargent</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>OP</given-names>
            </name>
          </person-group>
          <article-title>Haematological emergencies managing hypercalcaemia in adults
and children with haematological disorders</article-title>
          <source>Br J Haematol</source>
          <year>2010</year>
          <volume>149</volume>
          <issue>4</issue>
          <fpage>465</fpage>
          <lpage>477</lpage>
          <pub-id pub-id-type="pmid">20377591</pub-id>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerdudo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Aerts</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fattet</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chevret</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pacquement</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Doz</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hypercalcemia and childhood cancer: a 7-year
experience</article-title>
          <source>J Pediatr Hematol Oncol</source>
          <year>2005</year>
          <volume>27</volume>
          <issue>1</issue>
          <fpage>23</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">15654274</pub-id>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Ruza</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <source>Tratado de cuidados intensivos pediatricos</source>
          <edition>3&#xAA; ed</edition>
          <publisher-loc>Madri</publisher-loc>
          <publisher-name>Norma-Capitel Ediciones</publisher-name>
          <year>2003</year>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pradhan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leonard</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Calcium-free hemodialysis for hypercalcemia of malignancy in
a newborn</article-title>
          <source>Pediatr Nephrol</source>
          <year>2003</year>
          <volume>18</volume>
          <issue>5</issue>
          <fpage>474</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="pmid">12687453</pub-id>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Shiang</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>CC</given-names>
            </name>
          </person-group>
          <article-title>Hypercalcemic crisis successfully treated with prompt
calcium-free hemodialysis</article-title>
          <source>Am J Emerg Med</source>
          <year>2009</year>
          <volume>27</volume>
          <issue>9</issue>
          <fpage>1174.e1</fpage>
          <lpage>1174.e3</lpage>
          <pub-id pub-id-type="pmid">19931789</pub-id>
        </element-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Au</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dunham</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Godinez</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Treatment of medically refractory hypercalcemic
crisis</article-title>
          <source>Int J Artif Organs</source>
          <year>2012</year>
          <volume>35</volume>
          <issue>7</issue>
          <fpage>538</fpage>
          <lpage>541</lpage>
          <pub-id pub-id-type="pmid">22476881</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kindgen-Milles</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kram</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kleinekofort</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Morgera</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Treatment of severe hypercalcemia using continuous renal
replacement therapy with regional citrate
anticoagulation</article-title>
          <source>ASAIO J</source>
          <year>2008</year>
          <volume>54</volume>
          <issue>4</issue>
          <fpage>442</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="pmid">18645366</pub-id>
        </element-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camus</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Charasse</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jouannic-Montier</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Seguin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tulzo</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Bouget</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Calcium free hemodialysis: experience in the treatment of 33
patients with severe hypercalcemia</article-title>
          <source>Intensive Care Med</source>
          <year>1996</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>116</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="pmid">8857118</pub-id>
        </element-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bahoush</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Miri-Aliabad</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Severe hypercalcemia: a rare and unusual presentation of
childhood acute lymphoblastic leukemia</article-title>
          <source>Int J Hematol Oncol Stem Cell Res</source>
          <year>2014</year>
          <volume>8</volume>
          <issue>2</issue>
          <fpage>38</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">24800038</pub-id>
        </element-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kreutle</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Blum</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Meier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Past</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sch&#xFC;tz</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bisphosphonate induced hypocalcemia - report of six cases
and review of the literature</article-title>
          <source>Swiss Med Wkly</source>
          <year>2014</year>
          <volume>144</volume>
          <fpage>w13979</fpage>
          <lpage>w13979</lpage>
          <pub-id pub-id-type="pmid">24964073</pub-id>
        </element-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minson</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Prasad</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vear</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Borinstein</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Domm</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>t(17;19) in children with acute lymphocytic leukemia: a
report of 3 cases and a review of the literature</article-title>
          <source>Case Rep Hematol</source>
          <year>2013</year>
          <volume>2013</volume>
          <fpage>563291</fpage>
          <lpage>563291</lpage>
          <pub-id pub-id-type="pmid">23346431</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
